Combination hormonal contraception and progestin-only contraception (including depot medroxyprogesterone acetate [DMPA]) are effective and convenient forms of reversible contraception that millions of women use worldwide. In recent years, observations of reduced bone mineral density in current users of these methods have led to concerns that this hormone-induced bone loss might translate into long-term increased fracture risk. Special focus has been placed on adolescent users who have not yet attained their peak bone mass as well as perimenopausal users. In 2004, the FDA added a black box warning to DMPA package labeling warning of the risk of significant bone loss and cautioning against long-term use (> 2 years). This article reviews evidence on the use of hormonal contraception and its effect on bone density in adolescent, premenopausal, and perimenopausal populations. Recommendations from reproductive healthcare organizations are reviewed and clinical recommendations are provided.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11154-011-9180-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Knowledge and attitude of deaf women in relation to contraceptive methods: A systematic review.
Clinics (Sao Paulo)
January 2025
Department of Obstetrics and Gynecology, Faculdade de Medicina, Universidade de São Paulo (FMUSP), São Paulo, SP, Brazil. Electronic address:
Background: Communication barriers make it difficult for deaf women to access information about contraceptive methods, making them vulnerable to unplanned pregnancies.
Objective: To identify knowledge and attitudes of deaf women in relation to contraceptive methods.
Method: The authors conducted a systematic review of the literature, PROSPERO registry (CRD42021277635), conducted from August 2021 to April 2024.
Cell-free DNA release following psychosocial and physical stress in women and men.
Transl Psychiatry
January 2025
Department of Genetic Psychology, Faculty of Psychology, Ruhr-University Bochum, Universitätsstraße 150, Bochum, Germany.
Cell-free DNA (cfDNA) is continuously shed by all cells in the body, but the regulation of this process and its physiological functions are still largely unknown. Previous research has demonstrated that both nuclear (cf-nDNA) and mitochondrial (cf-mtDNA) cfDNA levels increase in plasma in response to acute psychosocial and physical stress in males. This study further investigated these findings by testing 31 female participants (16 using oral hormonal contraception and 15 not using oral hormonal contraception), and the results were subsequently compared with those of 16 male participants.
View Article and Find Full Text PDFAssociation of willingness to use hormonal contraception with knowledge: a national survey.
Contraception
January 2025
Department of Obstetrics and Gynecology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239.
Objective: To determine if willingness to use and concern with using hormonal contraception (HC) is associated with knowledge about HC.
Study Design: We conducted an online cross-sectional survey of self-identified women, US residents 18 and older using Amazon Mechanical Turk and ResearchMatch.org.
Development of a transdermal gel for reversible male contraception.
Contraception
January 2025
Division of Endocrinology, Department of Medicine, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California; Clinical and Translational Science Institute, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California.
While there are several easy-to-use reversible female contraceptives, little is available for men. Introduction of novel, cost-effective male contraceptives could have important downstream global health and economic benefits. Currently, nearly half of all pregnancies globally are unintended, with many resulting in unsafe abortions, a significant burden for women and families in many countries.
View Article and Find Full Text PDFInvestigations of Long-Acting Formulations in Children, Adolescents, and Pregnant Women: A Systematic Review.
Pharmaceutics
January 2025
Division of Clinical Pharmacology, Department of Medicine, School of Medicine, The Johns Hopkins University, Baltimore, MD 21287, USA.
Long-acting and extended-release drug delivery strategies have greatly improved treatment for a variety of medical conditions. Special populations, specifically infants, children, young people, and pregnant and postpartum women, could greatly benefit from access to these strategies but are often excluded from clinical trials. We conducted a systematic review of all clinical studies involving the use of a long-acting intramuscular injection or implant in infants, children, young people, and pregnant and postpartum people.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!